Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 5/2013

01-10-2013 | Erratum

Erratum to: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer

Authors: Isamu Okamoto, Keisuke Aoe, Terufumi Kato, Yukio Hosomi, Akira Yokoyama, Fumio Imamura, Katsuyuki Kiura, Tomonori Hirashima, Makoto Nishio, Naoyuki Nogami, Hiroaki Okamoto, Hideo Saka, Nobuyuki Yamamoto, Naoto Yoshizuka, Risa Sekiguchi, Kazuhiro Kiyosawa, Kazuhiko Nakagawa, Tomohide Tamura

Published in: Investigational New Drugs | Issue 5/2013

Login to get access

Excerpt

Erratum to: Invest New Drugs …
Metadata
Title
Erratum to: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer
Authors
Isamu Okamoto
Keisuke Aoe
Terufumi Kato
Yukio Hosomi
Akira Yokoyama
Fumio Imamura
Katsuyuki Kiura
Tomonori Hirashima
Makoto Nishio
Naoyuki Nogami
Hiroaki Okamoto
Hideo Saka
Nobuyuki Yamamoto
Naoto Yoshizuka
Risa Sekiguchi
Kazuhiro Kiyosawa
Kazuhiko Nakagawa
Tomohide Tamura
Publication date
01-10-2013
Publisher
Springer US
Published in
Investigational New Drugs / Issue 5/2013
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-013-9994-z

Other articles of this Issue 5/2013

Investigational New Drugs 5/2013 Go to the issue

PRECLINICAL STUDIES

Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas

PRECLINICAL STUDIES

Role of IL-8 induced angiogenesis in uveal melanoma

PHASE I STUDIES

Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies

PHASE II STUDIES

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

PHASE I STUDIES

A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer

PHASE I STUDIES

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits